Otonomy, Inc. (OTIC)
Market Cap | 6.75M |
Revenue (ttm) | n/a |
Net Income (ttm) | -52.26M |
Shares Out | 57.15M |
EPS (ttm) | -0.77 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,077,162 |
Open | 0.112 |
Previous Close | 0.109 |
Day's Range | 0.108 - 0.123 |
52-Week Range | 0.060 - 2.590 |
Beta | 1.46 |
Analysts | Buy |
Price Target | 9.18 (+7,673.07%) |
Earnings Date | Feb 27, 2023 |
About OTIC
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the pr... [Read more]
Financial Performance
In 2021, Otonomy's revenue was $125,000, a decrease of -54.21% compared to the previous year's $273,000. Losses were -$51.18 million, 14.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for OTIC stock is "Buy." The 12-month stock price forecast is $9.18, which is an increase of 7,673.07% from the latest price.
News

Otonomy Announces Change in Stock Exchange Listing
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indica...

Otonomy Provides Corporate Update
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company's board of directors, after considering strategic options, has approved and adopted a Plan of...

5 Investors Betting Big on Otonomy (OTIC) Stock
Shares of Otonomy (NASDAQ: OTIC) stock are in the spotlight again today. Although it's in the red today, OTIC stock sports a five-day gain of more than 100%.

Why Is Otonomy (OTIC) Stock Up 97% Today?
Otonomy (NASDAQ: OTIC) stock is on the move Tuesday despite a lack of news from the biopharmaceutical company. Instead, it looks like traders have latched onto OTIC stock as the next big short squeez...

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss
SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the...

Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the...

Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. ET

Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update
SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will ...

Otonomy to Participate in the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its parti...

Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the prese...

Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. ET

Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will r...

Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss
SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positiv...

Otonomy to Host Virtual Investor R&D Event on March 22, 2022
SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it...

Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. ET

Otonomy to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that man...

Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus
SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the comp...

Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will ...

Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting
SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced two upc...

Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple...

Otonomy Reports Corporate and Product Pipeline Update
Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss expected during 2022

Otonomy to Participate in the H.C. Wainwright BioConnect Conference
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its part...

Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its part...

Otonomy (OTIC) Reports Q3 Loss, Lags Revenue Estimates
Otonomy (OTIC) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. ET